| Market Capitalization (Millions $) |
1,203 |
| Shares
Outstanding (Millions) |
152 |
| Employees |
895 |
| Revenues (TTM) (Millions $) |
349 |
| Net Income (TTM) (Millions $) |
42 |
| Cash Flow (TTM) (Millions $) |
22 |
| Capital Exp. (TTM) (Millions $) |
7 |
Mimedx Group Inc
MiMedx Group Inc is a leading biopharmaceutical company that develops and markets innovative regenerative biologics and biomaterial products. The company specializes in the research and development of advanced wound care products, tissue repair products, and human placental tissue-based products designed to promote healing and tissue regeneration.
Founded in 2008, MiMedx Group Inc is headquartered in Marietta, Georgia, USA, with additional operations in Europe and Asia. The company has grown to become a leading provider of advanced wound care products and regenerative biologics with its proprietary platform technology, Purion. These products are designed to provide a safe, effective, and cost-efficient solution to treat chronic wounds, surgical wounds, and other tissue injuries.
MiMedx's Purion platform technology allows for the creation of human placental tissue-based products that can be implanted to promote healing and tissue regeneration. The company's portfolio of products includes AmnioFixe and EpiFixe for advanced wound care and surgical applications, Purione for tissue repair and regeneration, and OrthoFloe for orthopedic applications.
AmnioFixe and EpiFixe are MiMedx's flagship products, which are derived from human amniotic membrane tissue. Both products are used to treat chronic and acute wounds, such as diabetic foot ulcers, pressure ulcers, venous leg ulcers, and surgical wounds. The products contain natural growth factors and other bioactive molecules that promote healing and tissue regeneration.
Purione is a new line of tissue repair and regeneration products that is expected to drive future growth for MiMedx Group Inc. This technology platform allows the processing and sterilization of human tissue to produce purified extracellular matrix (ECM) that can be used to repair, regenerate, and remodel tissue defects, such as bone, cartilage, and soft tissue.
OrthoFloe is MiMedx's newest product line that is designed to enhance the healing of orthopedic injuries and surgical procedures. This product is derived from human amniotic fluid and contains growth factors and other natural products that are beneficial for bone and tissue repair.
In addition to these products, MiMedx Group Inc also offers a range of training, education, and support services to healthcare professionals to ensure that their products are used effectively and safely. The company also works closely with healthcare providers to develop customized treatment plans and clinical protocols to ensure optimal patient outcomes.
MiMedx Group Inc is committed to advancing the field of regenerative medicine by developing and commercializing innovative products that improve patient outcomes, reduce healthcare costs, and enhance quality of life. With its proprietary technology platform and extensive product portfolio, MiMedx is well-positioned for continued growth and success in the years to come.
Company Address: 1775 West Oak Commons Court, NE Marietta 30062 GA
Company Phone Number: 651-9100 Stock Exchange / Ticker: NASDAQ MDXG
|
11.5% 
65.75 %